ClinicalTrials.gg
CompletedNCT00002252Updated Jun 24, 2005

A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea

An interventional study of Octreotide in Diarrhea and HIV Infections, sponsored by Sandoz. Completed at 23 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Sandoz (formerly part of Novartis) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Diarrhea by Novartis — none open to participants now, none under way, none of them phase 3. Diarrhea · Novartis.

No phase
2 of 13
none open now
Registered
1st of 13
by date

Among the 13 studies in Diarrhea by Novartis, this one is one of 2 with no phase, and was the 1st registered.

Diarrhea

879 studies on the registry are indexed under Diarrhea; 78 are open to participants now.

Browse Diarrhea studies →

Open to participants now

None of the 13 studies in Diarrhea by Novartis is open now. The open studies under Diarrhea, anywhere →

Who these studies take

Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Diarrhea by Novartis as a file.
02

Study summary

To determine the efficacy and safety of Sandostatin (octreotide) compared to placebo in controlling diarrhea which is a manifestation or complication of documented HIV infection and which is refractory (does not respond) to all known treatment classes.

03

Conditions studied

  • Diarrhea
  • HIV Infections

Keywords

  • Octreotide
  • Diarrhea
  • Acquired Immunodeficiency Syndrome
  • AIDS-Related Complex
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must have the following:

  • Uncontrolled diarrhea that is either a manifestation or complication of documented infection.
  • Ability to communicate, participate, and comply with the requirements of the study.
  • Capability of self administering injections of study medication or have responsible family member or companion who can.
  • Given written consent prior to study entry.

Prior Medication:

Required:

  • At least two weeks of conventional dosing regimens of antidiarrheal medication (e.g.:
  • Lomotil, Imodium, Paregoric) within one month prior to study entry. OR Patients with evidence of upper or lower GI infection(s) for which there is approved, potentially curative therapy must have failed appropriate treatment for at least two weeks.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

  • Evidence of underlying disease other than due to .
  • Diarrhea caused by a known gastrointestinal disorder such as idiopathic ulcerative colitis, Crohn's disease, acute stool culture positive bacterial colitis (documented within the last 2 weeks prior to study entry AND not having at least 2 weeks of antibiotic therapy), pseudomembranous colitis (Clostridium difficile toxin positive), short gut syndrome, chronic pancreatitis (alcoholic or idiopathic), ischemic bowel disease, or enteroenteric fistulae.

Patients with the following are excluded:

  • Diarrhea that can be controlled with conventional antidiarrheal agents.
  • Stool weight at either of the 2 baseline periods that average \< 500 g/day.
  • Evidence of underlying immunosuppressive disease other than due to HIV.
  • Diarrhea caused by other gastrointestinal disorders not related to HIV.

Prior Medication:

Excluded:

  • Previously treated with Sandostatin as an anti-diarrheal agent.
  • Experimental antidiarrheal drugs within one month of study entry.

Present intravenous drug abuse.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment

Interventions

06

Study locations

23 sites
  • USC School of Medicine
    Los Angeles, California 90033, United States
  • UCSD Med Ctr
    San Diego, California 92103, United States
  • UCSF - San Francisco Gen Hosp
    San Francisco, California 94110, United States
  • Kaiser Permanente Med Ctr
    San Francisco, California 94115, United States
  • San Mateo County Gen Hosp
    San Mateo, California 94403, United States
  • Med Service
    Miami, Florida 33125, United States
  • Emory Univ School of Medicine
    Atlanta, Georgia 30303, United States
  • Rush Presbyterian - Saint Luke's Med Ctr
    Chicago, Illinois 60612, United States
  • Maine Med Ctr Med Clinics
    Portland, Maine 04102, United States
  • Douglas Plesko
    Boston, Massachusetts 02115, United States
  • Boston City Hosp
    Boston, Massachusetts 02118, United States
  • Henry Ford Hosp
    Detroit, Michigan 48202, United States
  • Univ of Missouri at Kansas City School of Medicine
    Kansas City, Missouri 64108, United States
  • Einstein Med School
    Bronx, New York 10461, United States
  • Mount Sinai Med Ctr
    New York, New York 10029, United States
  • SUNY Stony Brook / Health Sciences Ctr
    Stony Brook, New York 117948121, United States
  • Portland Veterans Adm Med Ctr / Rsch & Education Grp
    Portland, Oregon 97210, United States
  • Buckley Braffman Stern Med Associates
    Philadelphia, Pennsylvania 19107, United States
  • Miriam Hosp / Family Healthcare Ctr at SSTAR
    Providence, Rhode Island 02906, United States
  • Univ TX Galveston Med Branch
    Galveston, Texas 77550, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Infectious Disease Physicians Inc
    Annandale, Virginia 22203, United States
  • Univ of Wisconsin School of Medicine
    Madison, Wisconsin 53792, United States
07

References and documents

Publications

  • Romeu J, Miro JM, Mallolas J, Sirera G, Tortosa F, Clotet B. Sandostatin (SMS-201-995) in the long-term management of chronic diarrhea in AIDS patients. Int Conf AIDS. 1991 Jun 16-21;7(2):272 (abstract no WB2362)
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00002252
Lead sponsor
Sandoz
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 1992. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Octreotide

Start the discussion